Related Experiment Videos
Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1
M G Bischof1, K Redlich, C Schiller
1Department of General and Experimental Pathology, University of Vienna Medical School, Austria.
Abstract:
A panel of synthetic analogs of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3] bearing one or multiple structural modifications at functionally or metabolically sensitive positions of the molecule, i.e., C-1, 16, 23, 26 and 27, were tested for their growth inhibitory and prodifferentiating potency in human colon adenocarcinoma-derived Caco-2 cells. With respect to the peak response elicited at 10(-8) M, 1 alpha,25-dihydroxy-16-ene-vitamin D3, 1 alpha,25-dihydroxy-23-yne-vitamin D3 and 1 alpha,25-dihydroxy-16,23Z-diene-vitamin D3 suppressed [3H]thymidine incorporation in confluent Caco-2 cells less than 1 alpha,25(OH)2D3. 1 alpha,25-dihydroxy-16,23e-diene-vitamin D3 was at least equipotent to the parent compound, whereas 1 alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 and most conspicuously 1 alpha,25-dihydroxy-26,27-hexafluoro-16-ene-23-yne- vitamin D3 reduced growth of Caco-2 cells to significantly (P < .05) lower levels than 1 alpha,25(OH)2D3. The same rank order was obtained for the ability of the vitamin D compounds to induce activity of the differentiation marker enzyme, alkaline phosphatase, in quiescent Caco-2 cells. Whereas the effect of the synthetic analogs on calcium uptake by cultured embryonic chick duodenum in general was less pronounced than that of 1 alpha,25(OH)2D3, the two most potent antimitogenic compounds, 1 alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 and 1 alpha,25-dihydroxy-26,27-hexafluoro-16-ene-23-yne-vitamin D3, elicited calcium mobilization from cultured neonatal mouse calvaria at a 10-fold lower concentration than the parent compound.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Synthetic vitamin D analogs show potent anti-cancer effects. Novel compounds, particularly those with modifications at C-26 and C-27, significantly inhibit colon cancer cell growth and promote differentiation more effectively than the parent compound.
Area of Science:
- Endocrinology
- Molecular Biology
- Cancer Research
Background:
- 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3) is a potent hormone regulating calcium and phosphate metabolism.
- Its analogs are being investigated for therapeutic potential in cancer due to their antiproliferative and prodifferentiating effects.
Purpose of the Study:
- To synthesize and evaluate novel vitamin D analogs with structural modifications at sensitive positions.
- To assess their potency in inhibiting growth and inducing differentiation in human colon adenocarcinoma cells (Caco-2).
- To compare their effects on calcium metabolism with the parent compound.
Main Methods:
- Synthesis of various 1 alpha,25-dihydroxyvitamin D3 analogs with modifications at C-1, C-16, C-23, C-26, and C-27.
- Assay of [3H]thymidine incorporation to measure cell growth inhibition in Caco-2 cells.
- Measurement of alkaline phosphatase activity as a differentiation marker in Caco-2 cells.
- Assessment of calcium uptake in embryonic chick duodenum and calcium mobilization in neonatal mouse calvaria.
Main Results:
- Several synthetic analogs demonstrated significant growth inhibition and differentiation induction in Caco-2 cells.
- 1 alpha,25-dihydroxy-16-ene-23-yne-vitamin D3 and 1 alpha,25-dihydroxy-26,27-hexafluoro-16-ene-23-yne-vitamin D3 were more potent than 1 alpha,25(OH)2D3 in inhibiting Caco-2 cell growth.
- These two potent analogs also induced calcium mobilization from mouse calvaria at a 10-fold lower concentration than 1 alpha,25(OH)2D3.
Conclusions:
- Structural modifications in vitamin D analogs can enhance antiproliferative and prodifferentiating activities.
- Specific analogs, like those with hexafluoro modifications at C-26, C-27, show superior efficacy against colon cancer cells.
- These findings suggest potential for developing novel vitamin D-based therapies for colorectal cancer.